Business Wire

CREDIT SUISSE AT1s: Pallas Partners forming Investor Group

21.3.2023 20:03:00 EET | Business Wire | Press release

Share

 

Overview

Pallas Partners LLP (“Pallas”) is building a group of holders of Credit Suisse’s Additional Tier 1 Bonds (“AT1s”) wiped out at the weekend as part of the Swiss government-mandated takeover of Credit Suisse by UBS. The group will pursue a multi-faceted litigation strategy to seek to mitigate losses suffered by holders of the AT1s and allow recoveries to be made, through focused litigation against those who have acted to deprive the AT1s of their contractual and other rights.

Pallas is holding an investor call at 4pm UK / 12pm NY on Wednesday 22 March 2023 to discuss the group and the litigation strategy. Please email CSAT1Investors@pallasllp.com for details on how to join the call.

The Investor Group

Since events over the weekend by which the Swiss government and regulators forced through a takeover of Credit Suisse by UBS, a term of which was to write down the AT1s to zero, Pallas has been working with AT1 holders and investors to explore options to recover losses and understand the value play through litigation.

Pallas and investors are focused on the actions of the Swiss authorities (FINMA, the Federal Council and others) to pass through last-minute legislation purportedly providing for this AT1 wipe-out which upended the established claims hierarchy allowing equity holders to remain in the structure to the detriment of the AT1s.

We are exploring a cohesive multi-jurisdictional strategy to be pursued by a cohesive group of international investors in the AT1s, to recover losses.

Investors will be eligible to join the investor group if they held AT1s as at 17 March 2023, or hold AT1s at present. There is no jurisdictional restriction.

The Litigation Strategy

In extraordinary circumstances such as these, it is imperative that investors work together to pursue a litigation strategy designed to litigate against the right defendants in the right jurisdictions. A fractured investor community, spending time litigating in the wrong places against the wrong defendants will not serve the interests of the AT1s, and will not drive recoveries for AT1 holders.

Pallas is therefore building out a litigation strategy which considers both local law remedies and also remedies outside of Switzerland given the international nature of investors and the places in which statements were made to the market regarding CS’ liquidity and solvency position.

Details of the proposed recoveries strategy will be shared on the call, and Pallas can provide more detailed advice once an investor is a member of the group (and subject to confirmation of AT1 holdings).

Investor Call

Pallas’ investor group will take place at 4pm UK / 12pm NY on Wednesday 22 March 2023.

Details of the call are available from CSAT1Investors@pallasllp.com.

About Pallas Partners

Pallas Partners is a London and New York elite litigation firm specialising in high stakes litigation, international arbitration and investigations at the very top end of the market, for the world’s most sophisticated clients. The firm litigates cutting edge and complex cases, including securities litigation in the UK and Europe.

Pallas and its lawyers have an extraordinary depth of experience in litigating matters relating to bank resolutions, bank wind-downs, government interventions and CoCo redemptions and cancellations. We have acted on bank and investor challenges in Iceland, Ireland, UK, Cyprus, Greece, Spain, Portugal, Austria and Ukraine, and have represented holders of CoCo bonds in challenging cancellations and early redemptions, through to the UK Supreme Court.

Pallas is currently representing lenders to Mozambican SPVs in the “tuna bond” litigation against, amongst others, Credit Suisse, before the English Courts. We are also representing Greensill investors with respect to claims against Credit Suisse. Pallas also has an extensive practice acting for special situations and distressed holders in designing and implementing litigation strategies to recover value and create leverage.

Pallas’ Managing Partner Natasha Harrison is leading this mandate. Natasha is one of the leading litigators of the most important investor disputes of the last decade. Natasha is top-ranked in Legal 500 and Chambers & Partners, and is described as a “leading banking litigator” in those publications. Super Lawyers and Lawdragon have named her as a leading commercial litigator and Who’s Who named her as a Restructuring Thought Leader for 2022. In 2021 she won Legal Advisor of the Year at the Women in Finance Awards, she was shortlisted for a Lifetime Achievement Award by the Law Society and for Managing Partner of the Year by Legal Business. She was also listed by Financial News as one of the 50 Most Influential Lawyers in 2022 and as one of the 100 Most Influential Women in European Finance in 2022.

The wider team includes Duane Loft in New York, Fiona Huntriss, Tracey Dovaston and Neil Pigott in London, all of whom have deep experience in these issues.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information


Media:
Camarco
Ed Gascoigne-Pees, Partner
Julia Tilley, Partner
+44 (0)7815 068 387

Investors:
Natasha Harrison: nharrison@pallasllp.com
Pallas AT1 team: CSAT1@pallasllp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release

VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Multi-Color Corporation Receives Court Approval of First Day Motions4.2.2026 22:30:00 EET | Press release

Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that it has received approval from the U.S. Bankruptcy Court for the District of New Jersey (the “Court”) for first day relief related to its prepackaged Chapter 11 filed on January 29, 2026. The approved relief affirms that the Company will operate in the normal course, pay all trade vendors and suppliers in full, and maintain a strong liquidity position during the restructuring. As part of this relief, the Court granted MCC immediate access to $125 million of $250 million in debtor-in-possession (“DIP”) new money financing, provided by certain holders of MCC’s secured first lien debt and its equity sponsor, CD&R. This funding will capitalize the business through the initial stages of the prepackaged Chapter 11 process. The Court also granted MCC authority to pay trade vendors and suppliers in full in the ordinary course, maintain wages and benefits without interruption, satisfy

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye